RYAH Group, Inc is an international organization specializing in the development and distribution of medicinal cannabis products. The company was created in 2014 to develop cannabis products that can treat various medical conditions. Its mission is to provide a wide range of cannabis products, which will address patients’ medical needs for pain in a novel and effective way.
The Ryah Group, Inc is a publicly traded company, and is focused on providing education, research, and consulting services to the medical cannabis industry. The company’s proprietary software, ‘Ryah,’ is a program that analyzes medical cannabis patients and tracks the success of their treatment. The company’s report focuses on the use of medical cannabis for pain. The report is based on RYAH’s proprietary data and analytics.
RYAH Group, Inc. (OTCQB: RYA), a company that provides management consulting to the medical cannabis industry, has published its 2015 Medical Cannabis Utilization Report (M-CUR). The report, which is the fourth annual in the series, examines the use of medical cannabis for the treatment of pain. The current M-CUR examines the use of medical cannabis for the treatment of chronic pain, the use of medical cannabis for the treatment of fibromyalgia, the use of medical cannabis for the treatment of neuropathic pain, the use of medical cannabis for other pain, and the use of medical cannabis for the treatment of nausea.
TORONTO, June 10-June 21 (GLOBE NEWSWIRE) — via InvestorWire — RYAH Group, Inc. (CSE:RYAH) (RYAH or the Company) is pleased to announce that its wholly owned subsidiary, RYAH Medtech Inc. (RYAH Medtech), has published a report on data on the use of medical cannabis in pain patients. The report presents data on the use of cannabis to treat pain problems by patients in the RYAH data ecosystem and indicates whether cannabis could be one of the alternative treatment solutions to reduce the problems associated with opioid use in the context of existing treatment options. The publication is based on feedback from more than 40,000 patients who contacted the RYAH data ecosystem. The report provides a breakdown by patient gender, top conditions associated with pain treatment, and associated types, and shows that pain is one of the top three conditions for medicinal cannabis treatment in the RYAH Data ecosystem, and also appears to be one of the most interesting symptoms for researchers. At the time of writing, one of the world’s largest cannabis clinical trials is focusing specifically on pain management, and according to a recent press release from RYAH, the RYAH Smart Dry Herb Inhaler has been selected as the device of choice for such a trial (RYAH Medtech recently made the first delivery of RYAH Smart Dry Herb Inhalers and RYAH cartridges to a UK clinic conducting the trial). RYAH’s data report on the use of cannabis for pain management comes at a crucial time, as research into alternatives to opioids in the treatment and potential effectiveness of chronic pain gains momentum, said Gregory Wagner, CEO of RYAH. The opioid crisis, which began with initial good intentions to treat pain more effectively, has led to a flood of opioid prescriptions that have increased from about 70 million prescriptions in the 1990s to more than 255 million in 2012. The goal of RYAH is to provide the tools necessary to effectively monitor and measure the dosage of herbal treatments, as well as analytical data, so that the industry can make more informed decisions about alternatives to opioid-based treatments. About the RYAH Group, Inc. RYAH Group, Inc. (RYAH) is a connected device and Big Data and technology company focused on predictive analytics of value in the global medical crop and nutraceutical consumer industries. The robust artificial intelligence platform collects and correlates patient data in a HIPAA-compliant manner, which should help doctors and patients personalize herbal treatments and better predict treatment outcomes. Data collection is important for clinics, physicians, pharmacies, pharmaceutical companies and licensed drug processors (LDPs) to track and manage the impact of prescribing on patients and demographics. With a strong portfolio of intellectual property, RYAH collects in-depth and insightful data throughout the patient and formulary lifecycle. Forward-looking statements Certain statements in this press release constitute forward-looking information within the meaning of applicable Canadian securities laws. The words may, will, could, will, intend, plan, anticipate, believe, estimate, expect and similar expressions, as they relate to the Company, mean forward-looking information. All statements not based on historical facts may constitute forward-looking information. Forward-looking statements in this press release include statements regarding (i) cannabis as a potential alternative treatment for various pain conditions; (ii) a previously announced clinical trial in the United Kingdom of the safety and efficacy of cannabis and cannabis for the treatment of patients with chronic pain; and (ii) the size of the market for medical cannabis. Readers are also cautioned against making assumptions in these forward-looking statements, including, but not limited to, the assumption that (i) the Company’s financial condition and development plans will not change due to unforeseen events; (ii) demand for and market opportunities for the Company’s and its subsidiaries’ products and/or cannabis as a potential alternative treatment for various pain conditions will continue; (iii) current and future economic conditions will affect the Company’s business, operations or ability to Forward-looking information reflects the Company’s current views and intentions with respect to future events and information available to the Company and is subject to certain risks, uncertainties and assumptions. Many factors could cause the actual results, performance or achievements expressed or implied by such forward-looking information to differ materially from those described herein if one or more of these risks or uncertainties actually occurs. These risks include, but are not limited to, risks associated with (i) general business and economic conditions in the regions in which the Company operates; (ii) the ability of the Company and its subsidiaries to meet key priorities (including the completion of acquisitions and strategic plans and the retention of key executives); (iii) the ability of the Company to integrate newly acquired businesses; (iv) the expected benefits of HIPAA-compliant RYAH user data and the expected results and experiences that users will derive from the use of RYAH. If any of these factors affect the Company in an unexpected way, or if the assumptions underlying the forward-looking information prove to be incorrect, actual results or events could differ materially from those anticipated. The forward-looking information contained in this press release is effective as of the date of this document and is qualified in its entirety by this cautionary statement. The Company undertakes no obligation to publicly update or revise any forward-looking information, except as required by applicable law. This press release contains market and industry data derived from third-party sources, including trade publications. The Company believes that industry data is accurate and that its estimates and assumptions are reasonable, but no assurance can be given as to the accuracy or completeness of such data. Third party sources generally state that the information they contain is from sources believed to be reliable, but no guarantee is given as to the accuracy or completeness of the information they contain. Although the data is considered reliable, the Company has not independently verified the data from the third-party sources referred to in this press release and has not tested the economic assumptions underlying these sources. RYAH Medtech Inc. Contact : Sophia Kleshchuk Customer Service +1 917 210 0543 [email protected] Gregory Wagner, Executive Director 917 210 0543 [email protected] Corporate Communication : InvestorBrandNetwork (IBN) Los Angeles, CA www.InvestorBrandNetwork.com 310.299.1717 Suite [email protected]